Neumora Therapeutics (NASDAQ:NMRA – Get Free Report) and Cidara Therapeutics (NASDAQ:CDTX – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, analyst recommendations, profitability, valuation, risk, institutional ownership and earnings.
Insider and Institutional Ownership
47.7% of Neumora Therapeutics shares are held by institutional investors. Comparatively, 35.8% of Cidara Therapeutics shares are held by institutional investors. 26.4% of Neumora Therapeutics shares are held by company insiders. Comparatively, 7.6% of Cidara Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Analyst Recommendations
This is a summary of recent recommendations and price targets for Neumora Therapeutics and Cidara Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Neumora Therapeutics | 0 | 4 | 5 | 0 | 2.56 |
| Cidara Therapeutics | 0 | 0 | 4 | 2 | 3.33 |
Risk & Volatility
Neumora Therapeutics has a beta of 2.59, suggesting that its stock price is 159% more volatile than the S&P 500. Comparatively, Cidara Therapeutics has a beta of 0.88, suggesting that its stock price is 12% less volatile than the S&P 500.
Profitability
This table compares Neumora Therapeutics and Cidara Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Neumora Therapeutics | N/A | -73.63% | -68.97% |
| Cidara Therapeutics | -289.05% | -69.64% | -33.73% |
Valuation & Earnings
This table compares Neumora Therapeutics and Cidara Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Neumora Therapeutics | N/A | N/A | -$235.93 million | ($1.53) | -0.97 |
| Cidara Therapeutics | $1.28 million | 130.77 | -$22.93 million | ($30.09) | -0.79 |
Cidara Therapeutics has higher revenue and earnings than Neumora Therapeutics. Neumora Therapeutics is trading at a lower price-to-earnings ratio than Cidara Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Neumora Therapeutics beats Cidara Therapeutics on 8 of the 14 factors compared between the two stocks.
About Neumora Therapeutics
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer’s disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson’s disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.
About Cidara Therapeutics
Cidara Therapeutics, Inc., a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.
Receive News & Ratings for Neumora Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neumora Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
